» Articles » PMID: 31986070

Siglecs As Immune Cell Checkpoints in Disease

Overview
Date 2020 Jan 28
PMID 31986070
Citations 184
Authors
Affiliations
Soon will be listed here.
Abstract

Sialic acid-binding immunoglobulin-type lectins (Siglecs) are expressed on the majority of white blood cells of the immune system and play critical roles in immune cell signaling. Through recognition of sialic acid-containing glycans as ligands, they help the immune system distinguish between self and nonself. Because of their restricted cell type expression and roles as checkpoints in immune cell responses in human diseases such as cancer, asthma, allergy, neurodegeneration, and autoimmune diseases they have gained attention as targets for therapeutic interventions. In this review we describe the Siglec family, its roles in regulation of immune cell signaling, current efforts to define its roles in disease processes, and approaches to target Siglecs for treatment of human disease.

Citing Articles

Siglec-E augments adipose tissue inflammation by modulating TRAF3 signaling and monocytic myeloid-derived suppressor cells during obesity.

Rakib A, Mandal M, Mamun M, Kiran S, Yasmen N, Li L Front Immunol. 2025; 16:1501307.

PMID: 39967660 PMC: 11832521. DOI: 10.3389/fimmu.2025.1501307.


Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.

Sun Q, Hong S Int J Mol Sci. 2025; 26(3).

PMID: 39941004 PMC: 11818636. DOI: 10.3390/ijms26031238.


Mutant glycosidases for labeling sialoglycans with high specificity and affinity.

Liang S, Tang Q, Guo X, Li Z, Guo Y, Chang J Nat Commun. 2025; 16(1):1427.

PMID: 39915445 PMC: 11802738. DOI: 10.1038/s41467-025-56629-9.


Proximity Labeling and Genetic Screening Reveal that DSG2 is a Counter Receptor of Siglec-9 and Suppresses Macrophage Phagocytosis.

Wu Y, You Y, Jiang T, He Y, Fan Q, Zeng X Adv Sci (Weinh). 2025; 12(9):e2406654.

PMID: 39813162 PMC: 11884560. DOI: 10.1002/advs.202406654.


Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives.

Hashimoto A, Hashimoto S Cancers (Basel). 2024; 16(23).

PMID: 39682280 PMC: 11640101. DOI: 10.3390/cancers16234094.